Video Transcription
Assaf Klein 00:02
Okay, good afternoon. Thank you for the opportunity to present Limaca Medical. I am Assaf Klein, CEO. When I think about cancer, it is personal to me. Two years ago, my wife was diagnosed with cancer. It was a very difficult year for us, but she got timely and accurate diagnosis and treatment, and today, two years later, she is cured and back to normal life, and actually, she's here with me today, so it's a good time. Our vision in Limaca Medical is to bring accurate and timely diagnosis to pancreatic cancer patients, similar to the good outcomes with my wife. The existing endoscopic biopsy procedure fails too many pancreatic cancer patients. The physician needs to go in with the endoscope, conduct many stabs, because each stab is only a fractional amount of tissue, and the tissue quality is very low. So we need to come back with the endoscope, conduct all the stabbing, go out, and repeat this procedure three, four, and even five times for each patient, and even then, one in five patients will need to come back for a repeated procedure, and these patients are counting their lives in months. Our mission in Limaca Medical is to improve these procedures significantly. The Precision GI is an automated high-speed rotational tissue cutting device that is designed to solve this problem. And I will show you how it works. Very simple. I am ready to use it one time in the endoscope, put it here, and with only one motorized actuation, a second motorized actuation, and the procedure is done, and the tissue quality is perfect, adequate for all diagnostic needs. The Precision GI is more accurate, more efficient, designed to eliminate the redo cases, and, most importantly, obtain much better tissue quality. Dr. Carlos Robles Miranda, one of the biggest names, highly appreciated in the field, participated in our clinical study, and he stated, after doing our cases with our product, that the quality of tissue is amazing. He hasn't seen something like that until today, and he has been working for many years, and he believes that the Precision GI will make a revolution in endoscopic biopsies. You can see here why. On the left, you can see images of clean, contiguous core biopsies taken with the Precision GI from the pancreas and from the liver. And here in the right corner, you can see bloody, fragmented tissue taken with a manual stabbing device. This is the difference. I believe you don't need to be a histopathology expert to understand which product you would prefer to use. The market opportunity here exceeds $1 billion, and we believe that with our breakthrough technology, we will be able to convert a significant portion of this procedure to Precision GI. Our main competition is these manual stabbing devices that you just saw, which all work the same and all fail, short for the physician and for the patient. There are some different companies competing with us, seeing the problem similarly as us, but just struggling with the technology behind us. What we have achieved in Limaca Medical until today is that we designed and freeze the product. We built a strong IP portfolio. We conducted clinical studies, and most importantly, we achieved breakthrough technology designation from the FDA and then cleared the device by the FDA, so it's ready to use. I came here this week from the Orlando Health Medical Center, one of the most important medical centers in GI. We conducted over there a series of excellent cases with Dr. Shyam Varadaraju, number one in GI endoscopy in the United States today. We did these cases for one of our evaluation cases for one of the leading strategic players in the field. We have a high level of interest from all the others, and we are ready for commercialization. We have a very strong team of experts. I will mention each one of them. I can speak a lot, but I will be brief. Todd Dollinger, founder of the Train Lines Group, is our chairman. Karl Ricenbo, with extensive background in M&A and BD. Dr. Yad Ha Maisi, our founder, head of endoscopy in the Rambam Medical Center. Seth Gross, our chief medical advisor, head of the NYU Langone GI department, and Vivek Kal, Senior Medical Advisor from Rochester. I have been leading the company since its establishment, and I have more than 20 years in the medical device industry, so we are well prepared. Okay, this is the Limaca story. We are thrilled to bring our breakthrough technology into the market. We are now initiating Round A, and we invite you to join us in our journey to bring hope to pancreatic cancer patients. Thank you very much. Thank you.
